Adaptive Biotechnologies Corp (ADPT) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Adaptive Biotechnologies is a commercial-stage company advancing immune medicine through two primary business areas: Minimal Residual Disease (MRD), led by the clonoSEQ diagnostic test, and Immune Medicine, which includes research services and a strategic collaboration with Genentech. The company operates as an accelerated filer on the NASDAQ.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $52.4 million | $41.9 million |
| Net Loss (GAAP) | $(29.8) million | $(47.5) million |
| Net Loss Per Share | $(0.20) | $(0.33) |
| Adjusted EBITDA | $(12.7) million | $(28.2) million |
| Cash & Marketable Securities | $232.8 million | $256.0 million (Dec 31, 2024) |
| Operating Cash Flow | $(28.5) million | $(38.4) million |
| Revenue Interest Liability | $133.6 million | $133.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 25% year-over-year, driven primarily by a 34% increase in MRD revenue ($43.7M vs. $32.6M). MRD service revenue grew $11.1M, fueled by a 36% increase in clonoSEQ test volume (23,117 tests vs. 17,040 tests).
- Expense Reductions: Total operating expenses decreased 9.5% to $82.0M. Research and Development (R&D) expenses dropped 20% to $24.2M due to reduced headcount and lower investment in drug discovery. Cost of revenue decreased 6% to $17.0M.
- Profitability Improvement: The net loss narrowed significantly by $17.7M compared to Q1 2024. Adjusted EBITDA deficit improved by $15.4M, with the MRD segment deficit shrinking by $13.1M.
- Collaboration Revenue: Immune Medicine revenue declined 6% to $8.7M, primarily due to a $1.1M decrease in revenue recognized from the Genentech collaboration agreement.
Outlook, Commentary, and Risks
- Medicare Coverage: In Q4 2024, the company obtained Medicare coverage for Mantle Cell Lymphoma (MCL). In April 2025, Palmetto GBA expanded coverage to include single time-point testing for MCL recurrence monitoring. The Medicare Clinical Laboratory Fee Schedule rate for clonoSEQ was updated to $2,007 per test, with episode pricing at $8,029.
- Liquidity: Management believes existing cash and marketable securities ($232.8M) are sufficient to fund operations for at least the next 12 months. The company has a Revenue Interest Purchase Agreement with OrbiMed, allowing for up to $125M in additional installments by September 2025.
- Forward-Looking Risks: Key risks include the ability to achieve market acceptance for clonoSEQ, reimbursement rate changes, reliance on the Genentech collaboration for future milestones (potential $1.8B remaining), and the novelty of immune medicine technologies. The company continues to incur losses and has an accumulated deficit of $1.33 billion.
Investor Verification Checklist
- Reimbursement Rates: Verify the sustainability of the new $2,007 Medicare per-test rate and the impact of the expanded MCL coverage on future test volumes.
- Genentech Milestones: Monitor progress on the Genentech collaboration, as future revenue is heavily dependent on regulatory and commercial milestones that are currently constrained from recognition.
- Revenue Interest Liability: Review the effective interest rate (8.8% as of March 31, 2025) and the company's ability to service the $133.6M liability through future revenue streams.
- Cost Structure: Assess whether the recent reductions in R&D and headcount will impact the long-term development pipeline for new immune medicine products.
- Cash Burn: Track the trend in operating cash flow usage ($28.5M in Q1) against the $232.8M cash balance to validate the 12-month liquidity runway.